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FLORENCE: A midwife success story 
Florence Nwokoro is a nurse/midwife in one of Ebonyi State’s 555 
health facilities. Before July 2016, she had never met a woman with 
pre-eclampsia (PE), a hypertensive disorder of pregnancy and the 
country’s leading cause of maternal death. Despite its contribution 
to 23 percent of the national maternal mortality rate, Florence had 
not been trained on PE detection, treatment, or management, or to 
administer magnesium sulphate (MgSO4) to women with severe pre-
eclampsia or those experiencing eclamptic convulsions. She could, 
however, recognize eclampsia, a complication of pre-eclampsia 
that can kill a woman and her baby; for an eclamptic woman, life-
saving interventions are not always successful.
Between June and July 2016, Florence attended an Ending 
Eclampsia-led training on proper detection of pre-eclampsia, 
administration of the MgSO4 loading dose for severe cases, and 
referral of PE/E patients to secondary facilities for management. 
Since then, she has seen three cases of hypertension during 
pregnancy and one woman with severe pre-eclampsia.
Florence’s pre-eclamptic patient, Ms. Blessing Okeke*, arrived 
at the health facility with a severe headache. Florence checked 
her blood pressure (BP), which was 180/120, and conducted a 
urinalysis that revealed 2++ proteins. 
*To protect her privacy, Blessing’s real name has been changed. 
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Highlights
• Pre-eclampsia is a condition of 
pregnancy marked by increased 
blood pressure and protein in 
urine after 20 weeks gestation. 
• High-quality antenatal care 
improves prevention and early 
detection of pre-eclampsia and 
can prevent progression to 
eclampsia. 
• Eclampsia is a life-threatening 
condition characterized by 
convulsions in women with PE. 
• Women in developing countries 
are 300 times more likely to die 
from eclampsia than women in 
developed countries. 
• It can be managed by 
administering antihypertensive 
drugs and magnesium sulphate 
(MgSo4). 
• MgSO4 is the safest and most 
effective treatment for severe  
pre-eclampsia and eclampsia,  
and is one of the 13 UN Life-
Sacing Commodities for Women 
and Children. 
• PE/E and other hypertensive 
disorders in pregnancy increase 
the risk of pre-term births, which 
can lead to low birth weight, 
anemia, and stunting. 
The Ending Eclampsia project seeks to expand access to proven, 
underutilized interventions and commodities for the prevention, 
early detection, and treatment of pre-eclampsia and eclampsia and 
strengthen global partnerships. 
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Ending Eclampsia in Ebonyi State
Ebonyi State is one of three states in 
Nigeria, where the Ending Eclampsia project 
provides similar trainings, mentoring, and 
supportive supervision focused specifically 
on PE/E detection, prevention, and treatment 
measures.                                                                                                         
Representing the Ministry of Health as the 
state’s Safe Motherhood Coordinator (SMC), 
Mary Jane Nwobodo’s mandate is to ensure 
babies born in Ebonyi and mothers are safe 
from pregnancy-related complications. Her role 
is to build health providers’, including midwives, 
capacity to support pregnant women during 
ANC visits, in labor, and during the postnatal 
period.                                                                                                            
If there are gaps in providers’ skills sets, it is 
Mary Jane’s job to work with partners like Ending 
Eclampsia, UNICEF, and UNFPA to bring them up 
to standard by providing supportive supervision 
and on-the-job trainings that span a range 
of potential maternal health complications, 
including management and treatment of PE/E 
and using non-pneumatic anti-shock garments 
to prevent hemorrhage. 
“The Ending Eclampsia project is doing this in 
an elaborate, effective way because devoting 
one hour to any issue is not enough, Mary 
Jane said. “Ending Eclampsia is training 
providers for two or three days at a time to 
really make sure that every provider knows 
what they need to know about PE/E.” 
                                                                                                                                                                                    
“I diagnosed her with severe pre-eclampsia 
and asked if she experienced it in previous 
pregnancies. This was her fifth pregnancy 
and she never had hypertension, but said her 
mother was hypertensive,” Florence said.
Florence prescribed an antihypertensive drug 
to lower Blessing’s BP, and then referred her to 
the mission hospital. Later that day, Blessing 
returned to the health facility. Her husband 
could not afford the cost of travel to the mission 
hospital, and she still had a severe headache 
and was having difficulty breathing. Her BP was 
now 190/130, which prompted Florence to give 
a second dose of antihypertensive drugs. 
Florence slept at the facility with Blessing, and 
woke at 2 a.m. to take her BP, which finally 
lowered to 180/100. To prevent the BP from 
increasing again, Florence administered a third 
dose of antihypertensive drugs.
“In the morning, I went with them to the mission 
hospital and we were there before 9 a.m.,” 
Florence said. “They never gave her magnesium 
sulphate, but hydralazine instead because she 
was only 26 weeks into her pregnancy. They 
discharged her after one week.”
Upon her return to the facility, Blessing 
had no signs of hypertension or PE-related 
symptoms.                                                                                           
“She is now 30 weeks and she goes to the 
mission hospital every Tuesday. She is healthy,” 
Florence said. 
FIGURE 1: Provider Knowledge of PE/E Prevention and 
Management 
(n=379) 
Ebonyi (%) National (%)
Calcium or 
aspirin as 
prophylaxis
33 14
Antihypertensive 
drugs
28 41
Magnesium 
sulphate
11 12
Calcium 
gluconate 
7 7
